Fang Zhao

Professor Emerita
Areas of Interest: Dosage forms, drug delivery, pharmacokinetics, compounding, and contract formulation lab services
Office:WEGPHR 222
Fang Zhao
Certifications:

Apple Teacher

Education:

Ph.D., University of Kansas
M.S., University of Kansas
B.A., University of Kansas

Research and Scholarship Interest

  • Extemporaneous compounding (sterile and non-sterile) and stability evaluation
  • Development and evaluation of oral, ophthalmic and parenteral formulations
  • Characterization of physicochemical properties of drugs and excipients

Recent Grants and Contracts

  • $22,700 Research Contract from Iuvo Biosciences, Rush-Henrietta, New York. Preformulation and formulation development of a parenteral drug candidate to support safety studies in animal models. Jun - Oct 2023.
  • $1,883 Faculty Research Award Program Grant from Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY. Aspirin Stability in a Novel Anhydrous Oral Vehicle. Sep 2021 – Aug 2022.
  • $21,050 Research Contract (co-investigator) from Iuvo Biosciences, Rush-Henrietta, New York. Formulation and process optimization of an ophthalmic drug product to support an ANDA. Aug 2021 – Dec 2022.
  • $23,385 Research Contract (co-investigator) from Iuvo Biosciences, Rush-Henrietta, New York. Re-formulation of an ophthalmic drug product to support a 505(b)(2) NDA. Jul 2019 – Aug 2020.
  • $6,800 contract (co-investigator) from Iuvo Biosciences, Rush-Henrietta, New York. Formulation of an oral drug candidate and evaluation in simulated GI fluids. Jul 2019 – Jan 2020.

Recent Journal Publications

  • Austin DL, Ahmadi A, Cutaia DR, Perkins JR, Zhao F, Gawronski KM. Stability of a Compounded Sublingual Buprenorphine Solution for Neonatal Opioid Withdrawal Syndrome. J Pediatr Pharmacol Ther. 28:710–713 (2023). https://doi.org/10.5863/1551-6776-28.8.710  
  • Li S, Gabriel JJ, Martinez MN, Longstaff DG, Coffey MJ, Zhao F. An exploratory study of a simplified approach to evaluate drug solubility in milk related vehicles. Pharm Technol Hosp Pharm. 8(1):20230006 (2023). https://doi.org/10.1515/pthp-2023-0006  
  • Martinez MN, Zhao F, Longstaff DG, Gabriel JJ, Coffey MJ. Evaluating the solubility of compounds intended for intramammary infusion based upon tests conducted across a range of milk matrices. PLOS ONE. 18(7):e0288780 (2023). https://doi.org/10.1371/journal.pone.0288780
  • Wojcinski J, Nathan K, Zhao F. In vitro assessment of compounded lurasidone suspensions for enteral feeding tubes. Hosp Pharm. 58:304-308 (2023). https://doi.org/10.1177/00185787221139421
  • Chen P, Mar Z, Giannetti A, Hughes S, Gilbert J, Zhao F. An Exploratory Study of a New Vancomycin Eye Drops Formulation for Extemporaneous Compounding. Hosp Pharm. 57:69-75 (2022). https://doi.org/10.1177/0018578720973885
  • DelMonte K, To C, Rashid K, Sayers M, Mendoza M, Zhao F, Camenisch T. Extension of Tamiflu Shelf-Life in Strategic Stockpile for Public Health. J Environ Sci Public Health 5:504-515 (2021). 
  • Uttaro E, Zhao F, Schweighardt A. Filling the gaps on the ISMP Do Not Crush list for immediate-release products. Int J Pharm Compd. 25:364-371 (2021). PMID: 34623961
  • Buga I, Uzoma J, Reindel K, Rashid K, Diep T, McCartan P, and Zhao F. Physical and chemical stability of dexamethasone sodium phosphate in intravenous admixtures used to prevent chemotherapy-induced nausea and vomiting. Hosp Pharm 56:215-220 (2021). https://doi.org/10.1177/0018578719888912  
  • Cheung M, Zhao F, and Dave V. Physical-chemical stability of compounded sildenafil 100-mg rapid-dissolving tablets. Int J Pharm Compd. 25:82-87 (2021). 
  • Uttaro E, Pudipeddi M, Schweighardt A, and Zhao F. To crush or not to crush: a brief review of novel tablets and capsules prepared from nanocrystal and amorphous solid dispersion technologies. Am J Health Syst Pharm. 78:389-394 (2021). https://doi.org/10.1093/ajhp/zxaa412.

Patents

  • F Zhao. Packaging solutions. US Patent No. US 9,527,617. Date of Patent: Dec 27, 2016.
  • F Zhao, V Barniak, M Coffey, and R Braun. Packaging solutions. US Patent No. 8,490,782 B2. Date of Patent: Jul 23, 2013.
  • S Burke, E Phillips, F Zhao, V Barniak, and J Salamone. Ophthalmic compositions comprising a branched, glycerol monoalkyl compound and a fatty acid monoester. US Patent No. 7,670,997 B2. Date of Patent: Mar 2, 2010

Recent Poster Presentations

  • Saei K, Schweighardt A, and Zhao F. Crushability analysis of immediate-release oral tablets and capsules approved by FDA in 2020-2022. 2023 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2023
  • Soper B, Osborn M, Messenger C, Cutaia K, and Zhao F. Chemical stability of aspirin in novel anhydrous oral vehicles. 2022 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2022.
  • Messenger C, Soper B, Cutaia K, and Zhao F. Formulation and stability of low-dose aspirin capsules for the use of aspirin desensitization. 2022 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2022.
  • Wojcinski J, To C, Nathan K, and Zhao F. Compounded lurasidone suspensions for enteral feeding tubes. 2021 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2021.
  • Cutaia DR, Perkins JR, Zhao F, Ahmadi A, and Austin D. In Vitro feasibility study of compounded sublingual buprenorphine solution for the treatment of neonatal abstinence syndrome. 2021 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2021.
  • DelMonte K, Camenisch T, and Zhao F. Shelf-life stability of expired Tamiflu. AACP (American Association of Colleges of Pharmacy) Annual Meeting. Jul 2021. 
  • Uttaro E, Zhao F, and Schweighardt A. Filling in the gaps on the ISMP Do Not Crush List. 2020 ASHP (American Society of Health-system Pharmacists) Midyear Clinical Meeting. Dec 2020

Additional Information